Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PPHM +8%, LAYN +7.1%, PRGS +2.6%, (Q3 pre-announcement)
M&A news:
- TEVA +7.4% (Teva Pharma enters into a definitive agreement under which CooperSurgical (COO) will acquire PARAGARD; also receives FDA Priority Review for first line use of TRISENOX)
- GIMO +1.6% (Hearing sell side out suggesting between $47-60/share takeout could be in the works)
Other news:
- ALDX +47.5% (announces positive results from Dry Eye Disease Phase 2a Clinical Trial; Statistically and clinically significant improvement across multiple sign and symptom endpoints)
- HTBX +9.3% (granted a Type C meeting with the FDA to discuss the registrational pathway for our non-small cell lung cancer trial with HS-110 in combination with Bristol Myers-Squibb's (BMY) Opdivo based upon maturing Phase 2 data)
- ZFGN +4.7% (presents data for ZGN-1061 )
- DWDP +2.7% (completes review of the portfolio composition of the three intended independent companies)
- EYES +2.4% (Director Gregg Williams discloses 41.64% active stake)
- WDC +1.9% (seeing after hours strength on reports of winning bid for Toshiba (TOSBF) chip unit)
- GPRO +1.9% (continued strength)
- TTD +1.5% (continued strength)
- MU +1.2% (ahead of AAPL product event)
- AMD +1% (ahead of AAPL product event)
- AAPL +0.8% (ahead of AAPL product event)
Analyst comments:
- CTIC +8% (initiated with a Buy at Jefferies)
- DB +3.5% (upgraded to Outperform from Market Perform at Keefe Bruyette)
- AA +2.5% (upgraded to Buy from Hold at Deutsche Bank)
- MTZ +2.2% (upgraded to Buy from Hold at Deutsche Bank)
- CMCSA +1.5% (upgraded to Buy from Neutral at MoffettNathanson)
- NKE +0.8% (initiated with a Outperform at Bernstein)